BCL2L1 and hepatocellular carcinoma: To better identify the mitochondrial changes induced by regorafenib that allow BCL-xL antagonism to synergistically induce cytotoxicity in hepatoma cells, we analyzed the protein levels of BCL-2 members with recognized importance in cell survival.